Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people;Consensus d'experts de la Société française de gériatrie et gérontologie et de la Société française de cardiologie, sur la prise en charge de la fibrillation atriale du sujet âgé

Geriatrie et Psychologie Neuropsychiatrie du Vieillissement

Volumn 11, Issue 2, 2013, Pages 117-143

  Hanon, Olivier ^a,b,c   Assayag, Patrick ^d,e,f   Belmin, Joel ^a,g,i   Collet, Jean Philippe ^d,h,i   Emeriau, Jean Paul ^a,j   Fauchier, Laurent ^d,k,l   Forette, Françoise ^a   Friocourt, Patrick ^a,m   Gentric, Armelle ^a,n,o   Leclercq, Christophe ^d,p,q   Komajda, Michel ^d,h,p   Le Heuzey, Jean Yves ^c,d,r  

^a Société Française de Gériatrie et Gérontologie   (France)

^b Paris Descartes University   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Filiale de Cardiologie Pédiatrique et Congénitale   (France)

^e BICÊTRE HOSPITAL   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g HÔPITAL CHARLES FOIX   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k SERVICE DE DERMATOLOGIE   (France)

^l UNIVERSITÉ DE TOURS   (France)

^m Centre Hospitalier de Blois   (France)

ⁿ SERVICE DE RHUMATOLOGIE   (France)

^o UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^p RENNES UNIVERSITY HOSPITAL   (France)

^q UNIVERSITÉ DE RENNES 1   (France)

^r HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Arrhythmia; Atrial fibrillation; Consensus; Elderly; French society of cardiology; French society of geriatrics and gerontology; Guidelines

Indexed keywords

ANTICOAGULANT AGENT;

AGED; BRAIN HEMORRHAGE; CARDIOLOGY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; COMORBIDITY; CONFERENCE PAPER; CONSENSUS; CONSENSUS DEVELOPMENT; FRANCE; FRENCH SOCIETY OF CARDIOLOGY; FRENCH SOCIETY OF GERIATRICS AND GERONTOLOGY; GERIATRIC ASSESSMENT; GERIATRICS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL SOCIETY; MORTALITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK FACTOR; VERY ELDERLY;

ARRHYTHMIA; ATRIAL FIBRILLATION; CONSENSUS; ELDERLY; FRENCH SOCIETY OF CARDIOLOGY; FRENCH SOCIETY OF GERIATRICS AND GERONTOLOGY; GUIDELINES;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; CAUSE OF DEATH; COMORBIDITY; FRANCE; GERIATRIC ASSESSMENT; GERIATRICS; HUMANS; INTRACRANIAL HEMORRHAGES; QUALITY OF LIFE; RISK FACTORS; SOCIETIES, MEDICAL; STROKE;

EID: 84880068975     PISSN: 21158789     EISSN: 21157863     Source Type: Journal    
DOI: 10.1684/pnv.2013.0407     Document Type: Article

References (114)

1. Fuster V, Ryden LE, Cannom DS, Crijns H.J., Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European heart rhythm association and the Heart rhythm society. Circulation 2006; 114:e257-354.
2. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M., Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-66.
3. Charlemagne A, Blacher J, Cohen A, Collet J., Dievart F, de Groote P, et al. Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hos-pitalization data. Arch Cardiovasc Dis 2011; 104: 115-24.
4. Le Heuzey J., Paziaud O, Piot O, Said M.A., Copie X., Lavergne T, et al. Cost of care distribution in atrial fibrillation patients: the Cocaf study. Am Heart J 2004; 147: 121-6.
5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault L.E., Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (Atria) Study. JAMA 2001; 285: 2370-5.
6. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
7. Psaty BM, Manolio TA, Kuller LH, Kronmal R.A., Cushman M., Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-61.
8. Kirchhof P, Auricchio A, Bax J, Crijns H., Camm J, Diener H, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German atrial fibrillation competence network and the European heart rhythm association. Europace 2007; 9: 1006-23.
9. Nieuwlaat R, Capucci A, Camm AJ, Olsson S.B., Andresen D., Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on atrial fibrillation. Eur Heart J 2005; 26: 2422-34.
10. Stewart S, Hart CL, Hole DJ, McMurray JJ Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21.
11. Miyasaka Y, Barnes ME, Gersh BJ, Cha S.S., Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted county, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.
12. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro J.M., D'Agostino RBS, et al. Development of a risk score for atrial fibrillation (Framingham heart study): a community-based cohort study. Lancet 2009; 373: 739-45.
13. Wattigney WA, Mensah GA, Croft JB Increasing trends in hospi-talization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003; 108: 711-6.
14. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA 1994; 271: 840-4.
15. Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang T.J., Larson MG, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007; 297: 709-15.
16. Thomas MC, Dublin S, Kaplan RC, Glazer N.L., Lumley T., Longstreth WTJ, et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008; 21: 1111-6.
17. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A., et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374: 525-33.
18. Healey JS, Baranchuk A, Crystal E, Morillo C.A., Garfinkle M., Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-9.
19. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen S.E., Schmieder RE Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55: 2299-307.
20. Disertori M, Latini R, Barlera S, Franzosi M.G., Staszewsky L., Maggioni AP, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-17.
21. Wang TJ, Larson MG, Levy D, Vasan RS, Leip E.P., Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation 2003; 107: 2920-5.
22. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (Seniors). Eur Heart J 2005; 26: 215-25.
23. Komajda M, Hanon O, Hochadel M, Follath F., Swedberg K, Gitt A, et al. Management of octogenarians hospitalized for heart failure in Euro heart failure survey I. Eur Heart J 2007; 28: 1310-8.
24. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
25. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers V.K., Steinberg JS Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J 2008; 155: 310-5.
26. Gami AS, Hodge DO, Herges RM, Olson E.J., Nykodym J., Kara T, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49: 565-71.
27. Forti P, Maioli F, Pisacane N, Rietti E., Montesi F, Ravaglia G. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment (MCI). Arch Gerontol Geriatr 2007; 44 (SUPPL. 1): 155-65.
28. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998; 98: 946-52.
29. Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-64.
30. Nieuwlaat R, Prins MH, Le Heuzey J, Vardas PE, Aliot E, Santini M., et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro heart survey on atrial fibrillation. Eur Heart J 2008; 29: 1181-9.
31. Mant J, Hobbs FDR, Fletcher K, Roalfe A., Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, Bafta): a randomised controlled trial. Lancet 2007; 370: 493-503.
32. Wolf PA, Mitchell JB, Baker CS, Kannel W.B., D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158: 229-34.
33. Wolf PA, Abbott RD, Kannel WB Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22: 983-8.
34. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
35. Gage BF, Waterman AD, Shannon W, Boechler M, Rich M.W., Radford MJ Validation of clinical classification schemes for predicting stroke: results from the National registry of atrial fibrillation. JAMA 2001; 285: 2864-70.
36. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D., Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association. Eur Heart J 2012; 33: 2719-47.
37. Lip GYH, Nieuwlaat R, Pisters R, Lane D.A., Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.
38. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke. 2003; 34: 122-6.
39. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser A.S., Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996; 27: 1760-4.
40. Miyasaka Y, Barnes ME, Gersh BJ, Cha S.S., Seward JB, Bailey KR, et al. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke 2005; 36: 2362-6.
41. Schwammenthal Y, Bornstein N, Schwammenthal E, Schwartz R., Goldbourt U, Tsabari R, et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National acute stroke israeli survey [NASIS]). Am J Cardiol 2010; 105: 411-6.
42. Bilato C, Corti M, Baggio G, Rampazzo D., Cutolo A, Iliceto S, et al. Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro. V.A. study). Am J Cardiol 2009; 104: 1092-7.
43. Knecht S, Oelschlager C, Duning T, Lohmann H., Albers J, Stehling C, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29: 2125-32.
44. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam study. Stroke 1997; 28: 316-21.
45. Kalantarian S, Stern TA, Mansour M, Ruskin JN Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med 2013; 158: 338-46.
46. Lane DA, Lip GYH. Quality of life in older people with atrial fibrillation. J Interv Card Electrophysiol 2009; 25: 37-42.
47. Mehall JR, Kohut RMJ, Schneeberger EW, Merrill W.H., Wolf RK Absence of correlation between symptoms and rhythm in "symptomatic" atrial fibrillation. Ann Thorac Surg 2007; 83: 2118-21.
48. Nergardh A, Frick M. Perceived heart rhythm in relation to ECG findings after direct current cardioversion of atrial fibrillation. Heart 2006; 92: 1244-7.
49. Kerr C, Boone J, Connolly S, Greene M., Klein G, Sheldon R, et al. Follow-up of atrial fibrillation: the initial experience of the Canadian registry of atrial fibrillation. Eur Heart J 1996; 17(Suppl. C): 48-51.
50. Dagres N, Nieuwlaat R, Vardas PE, Andresen D, Levy S., Cobbe S, et al. Gender-related differences in presentation, treatment, and out-come of patients with atrial fibrillation in Europe: a report from the Euro heart survey on atrial fibrillation. J Am Coll Cardiol 2007; 49: 572-7.
51. Levy S, Maarek M, Coumel P, Guize L., Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the Alfa study. The College of French cardiologists. Circulation 1999; 99: 3028-35.
52. Cooke G, Doust J, Sanders S. Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract 2006; 55: 130-4.
53. Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
54. Lawton MP, Brody EM Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-86.
55. Nemeroff CB. The curiously strong relationship between cardiovascular disease and depression in the elderly. Am J Geriatr Psychiatry 2008; 16: 857-60.
56. Fuster V, Ryden LE, Asinger RW, Cannom D.S., Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American society of pacing and electrophysiology. Circulation 2001; 104: 2118-50.
57. Hart RG, Pearce LA, Aguilar MI Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
58. Rash A, Downes T, Portner R, Yeo W.W., Morgan N., Channer KS A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (Waspo). Age Ageing 2007; 36: 151-6.
59. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I., Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
60. Gouin-Thibault I., Levy C, Pautas E, Cambus J., Drouet L, Mahe I, et al. Improving anticoagulation control in hospitalized elderly patients on warfarin. J Am Geriatr Soc 2010; 58: 242-7.
61. Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J., Mahe I, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med 2005; 118: 137-42.
62. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J., Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
63. Patel MR, Mahaffey KW, Garg J, Pan G, Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
64. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
65. Ruff CT, Giugliano RP, Antman EM, Crugnale S.E., Bocanegra T., Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (Engage AF-Timi 48). Am Heart J 2010; 160: 635-41.
66. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey J.S., Oldgren J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-72.
67. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin J.L., Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-94.
68. Connolly SJ, Eikelboom J, Joyner C, Diener H., Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
69. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453-60.
70. Connolly SJ, Pogue J, Hart RG, Hohnloser S.H., Pfeffer M., Chrolavi-cius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-78.
71. Ruiz-Nodar J.M., Marin F, Hurtado JA, Valencia J, Pinar E., Pineda J, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51: 818-25.
72. Lau E, Bungard TJ, Tsuyuki RT Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. J Am Geriatr Soc 2004; 52: 428-33.
73. Tilly-Gentric A. Anticoagulation in permanent atrial fibrillation after 75 years of age. Rev Med Interne 2002; 23: 834-9.
74. Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F., Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 2006; 166: 853-9.
75. Fang MC, Go AS, Chang Y, Hylek EM, Henault L.E., Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120: 700-5.
76. Palareti G, Leali N, Coccheri S, Poggi M., Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (Iscoat). Italian study on complications of oral anticoagulant therapy. Lancet 1996; 348: 423-8.
77. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349: 675-83.
78. Hylek EM, Evans-Molina C, Shea C., Henault LE, Regan S. Major hemorrhage and tolerability of warfarininthe first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-96.
79. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin 2008; 26: 157-67.
80. Torn M, Bollen WLEM, van der Meer FJM, van der Wall EE, Rosen-daal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527-32.
81. Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 2000; 320: 1036.
82. Hylek EM, Singer DE Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
83. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault L.E., Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-26.
84. Pautas E, Gouin-Thibault I, Debray M., Gaussem P, Siguret V. Hae-morrhagic complications of vitamin k antagonists in the elderly: risk factors and management. Drugs Aging 2006; 23: 13-25.
85. Beyth RJ, Quinn LM, Landefeld CS Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-9.
86. Gage BF, Yan Y, Milligan PE, Waterman A.D., Culverhouse R., Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National registry of atrial fibrillation (NRAF). Am Heart J 2006; 151: 713-9.
87. Kuijer PM, Hutten BA, Prins MH, Buller HR Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-60.
88. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-Bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest 2010; 138: 1093-100.
89. Shireman TI, Mahnken JD, Howard PA, Kresowik T.F., Hou Q., Ellerbeck EF Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130: 1390-6.
90. Gage BF, Birman-Deych E, Kerzner R., Radford MJ, Nilasena DS, Rich MW Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118: 612-7.
91. Poli D, Antonucci E, Testa S, Tosetto A., Ageno W, Palareti G. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian centres for anticoagulation. Circulation 2011; 124: 824-9.
92. Lip GYH, Frison L, Halperin JL, Lane DA Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-Bled (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 2011; 57: 173-80.
93. Aronow WS. Management ofatrial fibrillationinthe elderly. Minerva Med 2009; 100: 3-24.
94. Wyse DG. Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. J Interv Card Electrophysiol 2009; 25: 25-9.
95. Wyse DG, Waldo AL, DiMarco JP, Domanski M.J., Rosenberg Y., Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
96. Marshall DA, Levy AR, Vidaillet H, Fenwick E, Slee A., Blackhouse G, et al. Cost-effectiveness ofrhythm versus rate control inatrial fibrillation. Ann Intern Med 2004; 141: 653-61.
97. Van Gelder I.C., Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-73.
98. Olshansky B, Rosenfeld LE, Warner AL, Solomon A.J., O'Neill G, Sharma A, et al. The atrial fibrillation follow-up investigation of rhythm management (Affirm) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43: 1201-8.
99. Hallberg P, Lindback J, Lindahl B, Stenestrand U., Melhus H. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007; 63: 959-71.
100. Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page R.L., Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-78.
101. Kober L, Torp-Pedersen C, McMurray JJV, Gotzsche O, Levy S., Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-87.
102. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M., Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365: 2268-76.
103. Guize L, Thomas F, Bean K, Benetos A., Pannier B. Fibrillation atriale: prévalence, facteurs de risque et mortalité dans une vaste population française suivie 15 ans. Bull Acad Natl Med 2007; 191: 791-803, discussion 803-5
104. Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 1989; 19: 321-6.
105. Jeong JH. Prevalence of and risk factors for atrial fibrillation in Korean adults older than 40 years. J Korean Med Sci 2005; 20: 26-30.
106. Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol 2008; 52: 865-8.
107. Bonhorst D, Mendes M, Adragao P, De Sousa J, Primo J, Leiria E., et al. Prevalence of atrial fibrillation in the Portuguese population aged 40 and over: the Fama study. Rev Port Cardio. 2010; 29: 331-50.
108. Cea-Calvo L., Redon J, Lozano JV, Fernandez-Perez C, Marti-Canales JC, Llisterri JL, et al. Prevalence of atrial fibrillation in the Spanish population aged 60 years or more. The Prev-Ictus study. Rev Esp Cardiol 2007; 60: 616-24.
109. Stefansdottir H, Aspelund T, Gudnason V, Arnar DO Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011; 13: 1110-7.
110. de Rotrou J., Battal-Merlet L, Wenisch E., Chausson C, Bizet E, Dray F., et al. Relevance of 10-min delayed recall in dementia screening. Eur J Neurol 2007; 14: 144-9.
111. Belmin J, Pariel-Madjlessi S, Surun P., Bentot C, Feteanu D, Lefebvre des Noettes V, et al. The cognitive disorders examination (Codex) isa reliable 3-minute test for detectionofdementiainthe elderly (validation study on 323 subjects). Presse Med 2007; 36: 1183-90.
112. Barberger-Gateau P., Dartigues JF, Letenneur L. Four instrumental activities of daily living score as a predictor of one-year incident dementia. Age Ageing 1993; 22: 457-63.
113. Katz S, Ford AB, Moscowitz RW, Jackson B.A., Jaffe MW Studies of illness in the age. The index of ADL: a standardized measure of the biological and psychosocial function. JAMA 1963; 185: 914-9.
114. Clément J.P., Nassif RF, Léger JM, Marchan F. Mise au point et contribution à la validation d'une version française brève de la geriatric depression scale de Yesavage. L'Encéphale 1997; 23: 91-9.